Start here: a strong idea, unproven so far
The viral-persistence findings elsewhere in this Atlas point to an obvious treatment strategy: if virus lingers in tissue and drives symptoms, clearing it should help. That logic motivates trials of antiviral drugs and monoclonal antibodies aimed at the persistent reservoir.
It is one of the most promising and closely watched directions in long COVID research. It is also, so far, unproven in people. No treatment is approved for long COVID, and the trials testing this idea have mostly not shown the hoped-for benefit, which is the honest current state.
biologically grounded in viral persistenceantiviral RCT showed no benefitinvestigational; nothing approved
The rationale
Several lines of evidence suggest SARS-CoV-2 can persist in tissues for months, and that its presence correlates with symptoms. If a reservoir of active virus keeps provoking the immune system, then drugs that stop viral replication, or antibodies that neutralise and help clear the virus, might break that cycle.
This approach borrows from how persistent infections like HIV and hepatitis C are tackled. The strategy is scientifically serious, and a major review has laid out how to design the trials, including which patients to select and how long to treat, because the mechanisms are not yet fully understood. The same review draws lessons from decades of work on the HIV and hepatitis C reservoirs, where clearing a hidden virus proved far harder than expected, a sobering precedent for long COVID.
What the trials show so far
The results to date are sobering. A randomized trial of the antiviral nirmatrelvir-ritonavir, the drug in Paxlovid, given for fifteen days to people with long COVID, found no significant improvement over placebo in physical health at the primary timepoint.
That negative result does not kill the hypothesis, since the right drug, dose, duration, and patient subgroup may not yet have been tested, but it is a real caution against assuming antivirals will work. Several more trials, including of monoclonal antibodies and longer or combination regimens, are underway.
nirmatrelvir trial: no benefit at primary endpoint
Why it is still pursued
Despite the disappointing antiviral trial, the reservoir strategy remains a priority because the underlying biology is strong and the first attempts may simply have been imperfect. A short antiviral course might be too brief, or might help only the subgroup with a genuine active reservoir.
Monoclonal antibodies, longer antiviral courses, and combination approaches are being tested precisely because a single negative trial of one drug at one duration cannot rule out the whole idea. The hypothesis is being refined, not abandoned.
What it means for you
There is no approved antiviral or antibody treatment for long COVID, and taking antivirals off-label for it is not currently supported by evidence. Be especially cautious of clinics offering antiviral or antibody courses for long COVID outside of trials, often at high cost.
The constructive path, if you want to pursue this avenue, is to look for legitimate clinical trials. That way any treatment is monitored, free, and contributing to the evidence, rather than an expensive gamble on an unproven therapy.
How to read claims about it
This area is ripe for overselling because the rationale is compelling and patients are desperate. The honest questions are whether a controlled trial has shown the specific treatment helps, and whether it is offered through research rather than for profit. For now, no antiviral or antibody approach has proven benefit.
Hold this as one of the most promising directions in long COVID and a treatment that is not yet ready. Enthusiasm for the science and caution about paying for unproven courses are the same honest position.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether clearing persistent virus improves symptoms in the right patients.
- Which patients have an active reservoir that treatment could target.
- Whether longer antiviral courses or combinations work where short ones failed.
- Whether monoclonal antibodies against the reservoir help.
- How to measure the reservoir to select patients and judge response.
- Why the first antiviral trial showed no benefit.
What this means for you
Targeting persistent virus with antivirals or antibodies is one of the most promising, biologically grounded treatment ideas in long COVID, built on real evidence that the virus can linger and track with symptoms.
It is unproven: a nirmatrelvir trial showed no benefit, and no treatment is approved for long COVID. Pursue this avenue through legitimate clinical trials rather than paying for off-label antiviral or antibody courses outside research.
References
Each reference links to the source on PubMed, PMC, or the publisher.